Segment disclosures

Company overview

Adverum Biotechnologies, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 6 retained observations 4 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=advm:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2025-07-01 – 2025-09-300 USD20251112Open filing evidence
2025-01-01 – 2025-09-300 USD20251112Open filing evidence
2024-01-01 – 2024-12-311000000 USD20250415Open filing evidence
2024-07-01 – 2024-09-301000000 USD20251112Open filing evidence
2024-01-01 – 2024-09-301000000 USD20251112Open filing evidence
2023-01-01 – 2023-12-313600000 USD20250415Open filing evidence